COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America COVID-19 in MS and NMOSD patients in LATAM

Simple item page
dc.contributor.authorAlonso, Ricardo
dc.contributor.authorSilva, Berenice
dc.contributor.authorGarcea, Orlando
dc.contributor.authorCorrea Diaz, Patricio E.
dc.contributor.authordos Passos, Giordani Rodrigues
dc.contributor.authorRamirez Navarro, Deyanira A.
dc.contributor.authorGarcia Valle, Luis A.
dc.contributor.authorRodriguez Salinas, Luis C.
dc.contributor.authorNegrotto, Laura
dc.contributor.authorLuetic, Geraldine
dc.contributor.authorTkachuk, Veronica A.
dc.contributor.authorMiguez, Jimena
dc.contributor.authorDiaz de Bedoya, Fernando Hamuy
dc.contributor.authorGoiry, Lorna Galleguillos
dc.contributor.authorRamirez Sanchez, Nicia E.
dc.contributor.authorBurgos, Marcos
dc.contributor.authorSteinberg, Judith
dc.contributor.authorBalbuena, Maria E.
dc.contributor.authorMonterrey Alvarez, Priscilla
dc.contributor.authorLopez, Pablo A.
dc.contributor.authorYsrraelit, Maria C.
dc.contributor.authorLeon, Rosalba A.
dc.contributor.authorCohen, Aron Benzadon
dc.contributor.authorGracia, Fernando
dc.contributor.authorMolina, Omaira
dc.contributor.authorCasas, Magdalena
dc.contributor.authorDeri, Norma H.
dc.contributor.authorPappolla, Agustin
dc.contributor.authorPatrucco, Liliana
dc.contributor.authorCristiano, Edgardo
dc.contributor.authorTavolini, Dario
dc.contributor.authorNadur, Debora
dc.contributor.authorGranda, Ana M. Toral
dc.contributor.authorWeiser, Roberto
dc.contributor.authorCassara, Fatima Pagani
dc.contributor.authorSinay, Vladimiro
dc.contributor.authorCarcamo Rodriguez, Claudia
dc.contributor.authorLazaro, Luciana G.
dc.contributor.authorMenichini, Maria L.
dc.contributor.authorPiedrabuena, Raul
dc.contributor.authorOrozco Escobar, Geraldine
dc.contributor.authorCarra, Adriana
dc.contributor.authorChertcoff, Anibal
dc.contributor.authorSantos Pujols, Biany
dc.contributor.authorVrech, Carlos
dc.contributor.authorTarulla, Adriana
dc.contributor.authorCarvajal, Rene
dc.contributor.authorMainella, Carolina
dc.contributor.authorBecker, Jefferson
dc.contributor.authorPeeters, Liesbet M.
dc.contributor.authorWalton, Clare
dc.contributor.authorAlonso Serena, Marina
dc.contributor.authorNunez, Sebastian
dc.contributor.authorRojas, Juan, I
dc.date.accessioned2025-01-20T22:09:40Z
dc.date.available2025-01-20T22:09:40Z
dc.date.issued2021
dc.description.abstractBackground: There is no data regarding COVID-19 in Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America. Objective: The objective of this study was to describe the clinical characteristics and outcomes of patients included in RELACOEM, a LATAM registry of MS and NMOSD patients infected with COVID-19. Methods: RELACOEM is a longitudinal, strictly observational registry of MS and NMOSD patients who suffer COVID-19 and Dengue in LATAM. Inclusion criteria to the registry were either: (1) a biologically confirmed COVID-19 diagnosis based on a positive result of a COVID-19 polymerase chain reaction (PCR) test on a naso-pharyngeal swab; or (2) COVID-19-typical symptoms (triad of cough, fever, and asthenia) in an epidemic zone of COVID-19. Descriptive statistics were performed on demographic and clinical variables. The cohort was later stratified for MS and NMOSD and univariate and multivariate logistic regression analysis was performed to identify variables associated with hospitalizations/intensive critical units (ICU) admission. Results: 145 patients were included in the registry from 15 countries and 51 treating physicians. A total of 129 (89%) were MS patients and 16 (11%) NMOSD. 81.4% patients had confirmed COVID-19 and 18.6% were suspected cases. 23 (15.8%) patients were hospitalized, 9 (6.2%) required ICU and 5 (3.4 %) died due to COVID-19. In MS patients, greater age (OR 1.17, 95% CI 1.05 - 1.25) and disease duration (OR 1.39, 95%CI 1.14-1.69) were associated with hospitalization/ICU. In NMOSD patients, a greater age (54.3 vs. 36 years, p=<0.001), increased EDSS (5.5 vs 2.9, p=0.0012) and disease duration (18.5 vs. 10.3 years, p=0.001) were significantly associated with hospitalization/ICU. Conclusion: we found that in MS patients, age and disease duration was associated with hospitalization and ICU admission requirement, while age, disease duration and EDSS was associated in NMOSD.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.msard.2021.102886
dc.identifier.eissn2211-0356
dc.identifier.issn2211-0348
dc.identifier.urihttps://doi.org/10.1016/j.msard.2021.102886
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94341
dc.identifier.wosidWOS:000689354300013
dc.language.isoen
dc.revistaMultiple sclerosis and related disorders
dc.rightsacceso restringido
dc.subjectmultiple sclerosis
dc.subjectNMOSD
dc.subjectCOVID-19
dc.subjectregistries
dc.subjectLatin America
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleCOVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America COVID-19 in MS and NMOSD patients in LATAM
dc.typeartículo
dc.volumen51
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas